Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ann Ital Chir ; 94: 454-459, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38051517

RESUMO

AIM: Upon this topic, randomized trials regarding gastrectomized and combination therapy with gastrectomy and chemotherapy have been made and survival has been prolonged to 15 months. In this study, we aimed to present our results by retrospectively classifying them according to Yoshida classification in stage 4 gastric cancer patients who have been operated in the last 5 years. METHODS: The datas of 102 cases were collected prospectively and analyzed retrospectively between years 2016 and 2021. All cases were classified according to Yoshida classification. RESULTS: 22 (%21,5) cases in category 1, 35 (%34,3) cases in category 2, 30 (%29,4) cases in category 3 and 15 (%14,7) cases in category 4. Overall survival rate of 1,3 and 5 year period in category 1 patients were %90, %50 and %25 respectively. Mean survival time was 24 months. In category 2, overall survival rate of 1,3 and 5 years was %90, %50 and %25 respectively. Mean survival time was 18 months. In category 3, overall survival rate of 1,3 and 5 years was %50, %10 and %0 respectively. Mean survival time was 12 months. Lastly, in category 4, overall survival rate of 1,3 and 5 years was %40, %0 ve %0 respectively and mean survival time was 9 months. CONCLUSION: We found that gastric cancer tumors without peritoneal involvement and responding to effective chemotherapy had longer survival and disease-free survival after conversion surgery. KEY WORDS: Gastric Cancer, Yoshida Classification, Conversion Surgery.


Assuntos
Neoplasias Gástricas , Humanos , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/cirurgia , Neoplasias Gástricas/patologia , Estudos Retrospectivos , Estadiamento de Neoplasias , Terapia Combinada , Intervalo Livre de Doença , Gastrectomia/métodos
2.
J Pers Med ; 12(11)2022 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-36579503

RESUMO

BACKGROUND: Uterine canceris one of the most common pelvic tumors in females. Advanced stage uterine cancer only represents 15% of newly diagnosed cases; however, they are related with poor prognosis. Our aim was to analyze the benefits of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis due to uterine cancer. METHODS: At the Istanbul Umraniye Training and Research Hospital, Surgical Oncology Clinic, morbidity, overall survival and survival without progression were analyzed over the 5-year follow up. Twenty-two cases who had undergone cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to uterine-peritoneal carcinomatosis were included in this study. Cases were followed up in terms of postoperative morbidity-mortality, disease-free survival and overall survival. The cut off value for the peritoneal carcinomatosis index score was set at 15. Intraperitoneal chemotherapy consisting of cisplatin and doxorubicin was applied to all patients for 60 min after the suturation of the abdomen. RESULTS: Median age of the patients was 64.6 (43-72). Average PCI score was 12.8 (3-15). CC score was 0 in 16 (72.7%) cases, 1 in 3 cases and 2 in 3 cases. Of these patients, 12 of them were previously operated upon. Median stay at the hospital was 13.1 days. No major complications due to chemotherapy were reported. A Clavien-Dindo Grade 3 complication was observed in seven (31.8%) patients. Mortality was not observed in patients during their stay at the hospital. The 5-year disease-free survival and overall survival rates were 36.8 (36%) months and 45.3 (57%) months, respectively. CONCLUSIONS: We think that due to longer disease-free survival and overall survival, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should be preferred in peritoneal carcinomatosis due to uterine cancer patients having low peritoneal carcinomatosis index scores and manageable complication rates. However, prospective randomizedtrials with a high number of cases are needed for this subject.

3.
Chirurgia (Bucur) ; 117(3): 294-304, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35792540

RESUMO

Introduction: Sarcomas with mesenchymal origin located in the abdominal cavity or retroperitoneal space are rare. They might reach large dimensions due to the non-specific and late onset of clinical symptoms. In this study we aim to provide the outcomes of 38 cases. Methods: Thirty-eight patients, whose data had been registered and analyzed completely in a prospective manner, were enrolled in the study. Demographic Findings, Primary-Recurrent Status of the disease, surgical method applied (R0-1-2), additional organ resections, Morbidity and Mortality rates, HIPEC application, Histopathological results and overall survival outcomes during follow-up were evaluated in the enrolled cases. Results: Thirty-eight (38) patients were operated on due to soft tissue sarcomas located in the abdominal and retroperitoneal area. The mean age of patients was 57.63 +- 15.38. The localization rates of retroperitoneal, abdominal and visceral tumors were 28%, 58%, and 12%, respectively. The mean tumor size was 12.96 cm +- 9.62. Twenty-seven patients (71%) underwent R0 resection, 7 patients (18%) underwent R1 resection, 4 patients (10%) underwent R2 resection. Additionally, sarcomatosis was detected in 6 patients and these patients underwent Cytoreductive Surgery+HIPEC. The first 30-day mortality and morbidity rates were 10.5% (4 patients) and 44% (17 patients), respectively. Conclusion: Surgery is the gold standard treatment of this condition. The most important stage in the management of the condition is the discussion of these cases in multidisciplinary teams in centers experienced in this disease in terms of prognosis and local recurrence and deciding on the treatment strategy based on these discussions.


Assuntos
Sarcoma , Humanos , Prognóstico , Estudos Prospectivos , Estudos Retrospectivos , Sarcoma/patologia , Sarcoma/cirurgia , Resultado do Tratamento
4.
Clin Med Insights Oncol ; 15: 11795549211065308, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34949947

RESUMO

BACKGROUND: The number of cases of cervical cancer with recurrence and peritoneal carcinomatosis is limited. In our study, we aimed to present the results of cytoreductive surgery hyperthermic intraperitoneal chemotherapy treatment and its 3-year early period results in patients with peritoneal metastases due to cervical cancer. METHODS: Data of 306 patients who had undergone cytoreductive surgery hyperthermic intraperitoneal chemotherapy between May 2016 and 2021 because of intra-abdominal metastases were collected prospectively and evaluated retrospectively. Ten cases who had undergone cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy due to cervical peritoneal carcinomatosis were included in this study. RESULTS: Average time of operation was 5 (range = 3-6) hours, mean average of peritoneal carcinomatosis index score was 12.3 (range = 7-36), and mean average of completeness of cytoreduction score was 1 in 2 patients and 0 in 8 patients. No mortality was recorded in 30 days postoperatively. Four patients relapsed and died because of pneumonia, coronavirus disease, pulmonary embolism, and terminal illness. These patients died at 2, 5, 6, and 12 months, respectively. Six patients are still alive and early period tumor relapse has not been reported during their follow-ups. CONCLUSIONS: This study has a limited number of patients and the results are early period results. The follow-up of patients were not long term. Therefore, it is hard to say that cytoreductive surgery hyperthermic intraperitoneal chemotherapy could be of any benefit looking at the results. Long-term results should be waited. Also, multicentered randomized cohort study with large sample size is required to evaluate this invasive procedure.

5.
Ther Adv Urol ; 12: 1756287220975923, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33354230

RESUMO

BACKGROUND: Urinary system resections and reconstructions are needed in peritoneal carcinomatosis due to abdominal malignancies. The effect of hyperthermic intraperitoneal chemotherapy on these urological procedures after reconstruction remains uncertain. The aim of the study is to evaluate major urological interventions during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in complex abdominal malignancies with peritoneal carcinomatosis. METHODS: Forty-four cases underwent surgical intervention related to the urinary system among 208 cases who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy because of peritoneal carcinomatosis. Urinary system procedures performed in these patients (radical-partial cystectomy, partial ureter resection ureteroneocystostomy, ureteroureterostomy, nephrectomy) were evaluated in terms of postoperative morbidity-mortality and survival. RESULTS: Urinary system resections were performed during cytoreductive surgery in a total of 44 cases. The mean age was 54 years (20-73). Patients were diagnosed with peritoneal carcinomatosis due to colorectal cancer in 21 (47.8%), ovarian cancer in nine (20.4%), sarcomatosis in five (11.4%), cervical cancer in four (9%) and other cancers (mesothelioma, uterus, breast, gastric) in five (11.4%) cases. Total nephrectomy was performed in three cases and partial nephrectomy in one case. Cystectomy was performed in 21 cases; 16 of these were partial and five were total cystectomies. Ureteroureterocystostomy with double J was performed in four cases and ureteroneocystostomy in 12 cases. While Clavian-Dindo grade 3-4 complications were seen in nine cases (20.4%), three cases (6.8%) became exitus during the first 30-day follow-up. CONCLUSIONS: Although urinary system involvements have been regarded as inoperable in the past, we think that with adequate experience radical urinary interventions performed in suitable patients can be carried out with acceptable morbidity and mortality as seen in our series.

7.
Indian J Surg ; 77(Suppl 2): 407-11, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26730035

RESUMO

Porcine acellular dermal collagen (PDC), which is a biological material derived from processing porcine dermis, has already been used for urologic, gynecologic, plastic, and general surgery procedures up to now. The aim of this study is to investigate the effectiveness of PDC on wound healing as a dermal substitute in the rat model. Twenty Wistar albino rats were divided into two groups. Standard full-thickness skin defects were created on the back of the rats. In the control group (Group 1), the dressings moisturized with saline were changed daily. In the study group (Group 2), porcine dermal collagen was implanted onto each wound and fixed with 4-0 polypropylene sutures. Contraction percentages of wound areas were calculated on the third, seventh, tenth, and fourteenth days by using the planimetric program. On fourteenth day, the wound areas were excised for histopathological examination, inflammatory scoring, and evaluation of collagen deposition. The study group was superior to the control group in terms of inflammatory scoring, type I/type III collagen ratio, and wound contraction rates. Porcine dermal collagen may be used effectively and safely on full-thickness wounds as a current dermal substitute.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...